Calcium Hydroxylapatite vs Poly-L-Lactic Acid: Differences
Calcium hydroxylapatite (CaHA) and poly-L-lactic acid (PLLA) are the two collagen biostimulators most discussed in orofacial harmonization. Both stimulate collagen production and neither is reversed by hyaluronidase, but their clinical behavior is quite different: CaHA delivers some volume right away and also serves for contouring; PLLA does not sustain immediate volume and works in a diffuse, gradual way.
This guide compares the two classes at a review level, without brand names, dilution, or technique. Indication, preparation, areas, and quantities follow the instructions for use of each registered product and the decision of the licensed professional, according to the rules of their professional council. For the overview of all biostimulators, see the biostimulators overview.
What is each product, in practice?
Injectable calcium hydroxylapatite is made of microspheres of a mineral similar to the inorganic part of bone and teeth, suspended in a carrier gel. The product comes ready to use, in a syringe. Right after injection, the gel takes up space and gives volume; over the following weeks, the carrier is absorbed and the microspheres serve as a scaffold for new collagen.
Poly-L-lactic acid is a synthetic, biocompatible, absorbable polymer from the same family of materials used in sutures. The product comes as a lyophilized powder and must be reconstituted before use, according to the manufacturer. The volume seen right after injection comes largely from the reconstitution liquid and fades within a few days. The effect sought is the collagen produced in response to the microparticles, which appears gradually.
In Brazil, injectable dermal fillers, including CaHA and PLLA, are regulated by ANVISA (the Brazilian health regulatory agency) as high- or maximum-risk medical devices (classes III or IV) and can only be sold with registration. In March 2026, the agency published a safety notice about the use of these products outside approved indications, reinforcing that areas and volumes must follow the instructions for use. General guidance is on ANVISA's Safe Procedure page (in Portuguese).
Calcium hydroxylapatite vs poly-L-lactic acid: comparison
| Aspect | Calcium hydroxylapatite | Poly-L-lactic acid |
|---|---|---|
| Composition | Mineral microspheres in a carrier gel | Polymer microparticles in powder, reconstituted before use |
| Presentation | Ready-to-use syringe | Vial for reconstitution, per the manufacturer |
| Effect on the day | Some immediate volume, provided by the gel | Transient volume from the liquid, gone within days |
| Main mechanism | Initial volume followed by collagen stimulation | Collagen stimulation, with no sustained volume of its own |
| Use profile | Contour and projection in support areas; diffuse stimulation when the manufacturer allows | Diffuse volumization and firmness, gradually |
| Sessions | Usually one, with reassessment; more when the goal is stimulation | Usually more than one, with an interval set by the professional |
| Described duration | Long, varying with product, area, and patient | Long, varying with product, number of sessions, and patient |
| Reversal | Not broken down by hyaluronidase | Not broken down by hyaluronidase |
| Imaging | Radiopaque, can show on X-ray and CT | Generally does not show on X-rays |
| Point of attention | Avoid areas of thin, highly mobile skin | Preparation and distribution per the manufacturer; nodules and papules |
Duration is deliberately left as "long": figures vary between manufacturers, areas, and patients, and should not be repeated to the patient as a promise. For the duration conversation with the patient, see how long a biostimulator lasts.
When does calcium hydroxylapatite usually make more sense?
CaHA tends to be chosen when the plan calls for structure: some volume on the day and a firm material that helps draw the contour. Situations often cited:
- Defining the jawline and the jaw angle.
- Projection and support of the cheekbone and the zygomatic area.
- Patients who want to see some change right after the procedure, without giving up collagen stimulation.
- Laxity plans in which the manufacturer allows diluted use for stimulation, per the package insert.
For the same reason, it calls for more caution where the skin is thin or the muscles are very mobile. Lips, the periorbital region, and superficial areas are usually avoided, because a firm, non-reversible material easily becomes palpable or visible.
When does poly-L-lactic acid usually make more sense?
PLLA is designed for tissue quality and diffuse volume, built up gradually. It fits better in:
- Global volume loss in the middle and lower thirds, where the goal is not to draw a point but to restore thickness to the tissue.
- Mild to moderate laxity, with skin that looks "tired".
- Patients who prefer a gradual change, less noticeable to others in the short term.
- Long-term plans in which the patient accepts more than one session.
It is not the choice for someone who wants a defined contour on the day, or who has an event coming up. The number of sessions and the interval are the professional's decision; the conversation with the patient about this is in how many biostimulator sessions.
Which risks are shared by both and which are specific to each?
The risks of any injectable apply to both: swelling, bruising, pain, infection, asymmetry, and vascular events. What changes the weight of these risks is the absence of enzymatic reversal. With hyaluronic acid, an excess or irregularity can be treated with an enzyme; with CaHA and PLLA, it cannot.
| Risk | Calcium hydroxylapatite | Poly-L-lactic acid |
|---|---|---|
| Early non-inflammatory nodule | Linked to thin-skin areas, a superficial plane, and local excess | Linked to inadequate preparation, distribution, and plane |
| Late nodule and granuloma | Rare, described in the literature | Rare, described in the literature |
| Vascular event | Possible; no enzymatic reversal | Possible; no enzymatic reversal |
| Visibility in thin skin | Higher, because it is a firm, white material | Lower on the day, but nodules can become palpable |
The general contraindications in facial harmonization apply to both. Active autoimmune disease, a tendency toward keloids, and a history of nodules with other fillers call for extra caution, and the medical history should record them.
Can both be used in the same plan?
They can, and it is common in full-face plans: CaHA or hyaluronic acid where the goal is structure, PLLA where the goal is diffuse stimulation. The order, the interval, and the division by area are the professional's decisions, with two practical precautions:
- Know what came from where. Injecting different products into the same area at the same time makes it harder to assess the response and to investigate a complication.
- Record everything. Product, lot, area, date, and amount of each injection in the patient record. Late nodules require reconstructing that history, sometimes years later.
Layered planning for the full face is covered in full-face biostimulator.
How to explain the difference to the patient
The patient arrives with the brand name they saw on social media and wants to know "which is better". The honest answer is that they are different tools. A simple way to put it:
This conversation is also the moment to separate biostimulator from filler. If that is the patient's question, use biostimulator or filler. The informed consent should record that the product has no enzymatic reversal; a starting point is the biostimulator informed consent template.
And in Harmy?
In Harmy, the Plan records ml per area (Cheekbone, Jawline, and the other points) and the projection shows the likely visual effect of that volume, changing only the marked areas. It does not simulate PLLA's gradual gain in firmness or the stimulation part of CaHA: the prompt prohibits skin retouching. When the plan includes a volume component, the projection helps with the conversation about that part; the effect on skin quality is left to verbal explanation.
For slow-response treatments, "Add actual result" in History stores the follow-up photo aligned by the eyes, which makes it easier to show progress without relying on the patient's memory. See history and actual result.
Checklist before choosing between the two
- Goal defined: contouring with some immediate volume, or diffuse, gradual stimulation.
- Area compatible with the instructions for use of the chosen product.
- Product's ANVISA registration checked.
- Skin thickness and mobility of the area assessed.
- Patient aware that hyaluronidase cannot reverse it.
- Number of sessions and intervals agreed (mainly for PLLA).
- Patient told to mention the procedure on imaging (CaHA).
- Standardized before photos and complete documentation in the patient record.
Frequently asked questions
What is the difference between calcium hydroxylapatite and poly-L-lactic acid?
Calcium hydroxylapatite comes as a ready-to-use gel with mineral microspheres and gives some volume right at injection, followed by collagen stimulation. Poly-L-lactic acid comes as a powder to be reconstituted, does not sustain immediate volume, and works only through gradual stimulation, usually over more than one session.
Which is better, calcium hydroxylapatite or poly-L-lactic acid?
There is no absolute best. The choice depends on the goal (contouring with some immediate volume or diffuse, gradual stimulation), the area, skin thickness, the product's approved indications, and the experience of the licensed professional.
Does hyaluronidase dissolve calcium hydroxylapatite or poly-L-lactic acid?
No. Hyaluronidase only breaks down hyaluronic acid. Neither biostimulator has enzymatic reversal, which weighs on the indication, the amount, and the choice of area.
Does calcium hydroxylapatite show up on imaging?
It can. Hydroxylapatite microspheres are radiopaque and can be seen on X-rays and CT scans. It is worth advising patients to mention the procedure when they have imaging of the face.
Harmy images are illustrative simulations generated by AI from the patient's photo to support the conversation between practitioner and patient. They are not a promise of results. Indication, technique, product and volume are solely the decision of the licensed practitioner. This content is for information only and does not replace a clinical assessment.